Patient Needs

Despite the many drugs now available, a substantial proportion of patients fail to respond adequately, if at all, to the available treatments for the disorders that NeuraWell is targeting (MDD, TRD, treatment-resistant anxiety).  Those patients carry a heavy burden of mental and physical suffering, comorbidity with other diseases, shortened lifespan, and high economic and social costs.

Treatment-resistant depression:

It is estimated that more than 30% of MDD patients are treatment-resistant and their life expectancy is shortened by 7-11years. [1]

Treatment-Resistant Anxiety:

Anxiety disorders are the most prevalent mood disorders affecting over 30% of Americans at least once in a lifetime [2]. Some episodes resolve with the use of selective serotonin reuptake inhibitors (SSRIs) or psychotherapies such as Cognitive Behavioral Therapy (CBT). Unresolved symptoms of severe anxiety may require problematic long term augmentation with benzodiazepenes or anti-psychotics. There is a substantial gap in safe and effective long-term treatments for Treatment Resistant Anxiety.

 
[1] US DHHS, Agency for Healthcare Research and Quality, “Treatment-Resistant Depression: A Narrative and Systematic Review of Definitions and Methods in Clinical Research Studies” Project ID:  PSYT0816, Dec 2016
[2] Harvard Medical School, 2007. National Comorbidity Survey (NCS). (2017, August 21). Retrieved from https://www.hcp.med.harvard.edu/ncs/index.php. Data Table 1: Lifetime prevalence DSM-IV/WMH-CIDI disorders by sex and cohort.